Kinexis, Inc. is a life science R&D company targeting pathology-linked oligomeric conformations of amyloid proteins involved in neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease and prion (Creutzfeld-Jakob) disease. Its strategy is to leverage a revenue-generating product stream through sponsored research and by forming relationships with major pharmaceutical and biotechnology companies.

Kinexis' proprietary technology allows generation of antibody responses specific for cytotoxic conformations of multiple amyloid proteins. Kinexis is commercializing its technology through development of biopharmaceutical products based on active immunization, passive immunotherapy, and small molecule screening strategies. Using its proprietary immunization technology, Kinexis has already identified product opportunities for Alzheimer's disease where active immunization and passive immunotherapy strategies have yielded dramatic pharmacological effects in animal models. 

Click Here to contact us about the Kinexis Inc..

InvestBio structures institutional quality investment opportunities for the qualified individual investor. Our scientific advisors have access to valuable industry insights, allowing us to identify the most promising research and drugs. We structure an investment partnership for our clients and typically invest side-by-side, at the same price and timing, in targeted private equity investments. This approach allows our interests to be directly aligned with our investors. On Wall Street, these investment opportunities are often only accessible to institutional investors, however, we at InvestBio believe that these opportunities should also be available to the qualified individual investor. We make that happen. InvestBio is a wholly owned subsidiary of DPEC Partners.